Welcome to the UPF Digital Repository

The challenge of developing human 3D organoids into medicines

Show simple item record

dc.contributor.author Vives, Joaquim
dc.contributor.author Batlle Morera, Laura
dc.date.accessioned 2020-05-12T07:22:41Z
dc.date.available 2020-05-12T07:22:41Z
dc.date.issued 2020
dc.identifier.citation Vives J, Batlle-Morera L. The challenge of developing human 3D organoids into medicines. Stem Cell Res Ther. 2020 Mar 4; 11(1): 72. DOI: 10.1186/s13287-020-1586-1
dc.identifier.issn 1757-6512
dc.identifier.uri http://hdl.handle.net/10230/44498
dc.description.abstract The capacity of organoids to generate complex 3D structures resembling organs is revolutionizing the fields of developmental and stem cell biology. We are currently establishing the foundations for translational applications of organoids such as drug screening, personalized medicine and launching the future of cell therapy using organoids. However, clinical translation of organoids into cell replacement therapies is halted due to (A) a few preclinical studies demonstrating their efficacy and (B) the lack of robust, reproducible, and scalable methods of production in compliance with current pharmaceutical standards. In this issue of Stem Cell Research & Therapy [ref], Dossena and collaborators present a validated bioprocess design for large-scale production of human pancreatic organoids from cadaveric tissue in accordance with current good manufacturing practice. The authors also propose a set of specifications of starting materials and critical quality attributes of final products that are of interest to other developments provided that this type of medicines are different than any other medicinal product due to their complex composition and living nature of the active ingredient. Although large-scale production of functional cells secreting insulin is still a challenge, the development of methods such as the one presented by Dossena and collaborators contributes to move toward clinical use of organoids in the treatment of type 1 diabetes and opens avenues for future clinical use of organoids in degenerative pathologies.
dc.description.sponsorship Work in JV’s laboratory is supported by the Spanish Cell Therapy Network (TerCel, expedient no. RD16/0011/0028), awarded by Generalitat de Catalunya as Consolidated Research Group (ref. 2017-SGR-719). Project PI19/ 01788 is funded by Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF) - A way to build Europe
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher BioMed Central
dc.rights © 2020 by Joaquim Vives, Laura Batlle-Morera. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated
dc.rights.uri http://creativecommons.org/licenses/by/4.0/
dc.rights.uri http://creativecommons.org/publicdomain/zero/1.0/
dc.subject.other Organoids
dc.subject.other Pàncrees
dc.subject.other Medicina regenerativa
dc.subject.other Enginyeria de teixits
dc.title The challenge of developing human 3D organoids into medicines
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1186/s13287-020-1586-1
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion

This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account


Compliant to Partaking